Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2022 06:30 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that...
February 28, 2022 16:05 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline Data from Phase 1 Trial Expected in the Second Half of 2022 CARLSBAD, Calif., Feb. 28, 2022 (GLOBE...
February 10, 2022 06:30 ET | Source: Design Therapeutics, Inc.

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that...
February 01, 2022 16:05 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that...
November 09, 2021 16:05 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Clinical Initiation of Lead GeneTACTM Program for Friedreich Ataxia On-track for the First Half of 2022 CARLSBAD, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN),...
September 08, 2021 06:30 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing small molecule treatments for degenerative genetic disorders, today...
August 09, 2021 16:05 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon,...
June 07, 2021 16:10 ET | Source: Design Therapeutics, Inc.

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that...
June 07, 2021 16:05 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Expands Board of Directors with Key Appointments

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the...
May 10, 2021 16:05 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development Company On-track to Initiate Phase 1 Clinical Trial...